Interdisciplinary recommendations on targeted therapy in the treatment of renal cell carcinoma;Interdisziplinäre Therapieempfehlungen zur Behandlung des Metastasierten Nierenzellkarzinoms

Aktuelle Urologie

Volumn 38, Issue 4, 2007, Pages 328-330

  Miller, K ^a,b   Bergmann, L ^a   Albers, P ^a   Jager E ^a   Jakse, C ^a   Geschwend, J E ^a   Marschner, N ^a  

^a Interdisziplinäre Arbeitsgruppe Nierenzellkarzinom der DKG ^*  (Germany)

^b CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

Immunotherapy; Metastases; Renal cell cancer; Targeted therapy

Indexed keywords

ALPHA INTERFERON; ANTINEOPLASTIC AGENT; BENZENESULFONIC ACID DERIVATIVE; BIOLOGICAL RESPONSE MODIFIER; INDOLE DERIVATIVE; PROTEIN KINASE INHIBITOR; PYRIDINE DERIVATIVE; PYRROLE DERIVATIVE; SORAFENIB; SUNITINIB;

ARTICLE; CONSENSUS DEVELOPMENT; CONTROLLED CLINICAL TRIAL; HUMAN; IMMUNOTHERAPY; KIDNEY; KIDNEY CARCINOMA; KIDNEY TUMOR; META ANALYSIS; METASTASIS; MORTALITY; NEPHRECTOMY; PATHOLOGY; PROGNOSIS; TIME;

ANTINEOPLASTIC AGENTS; BENZENESULFONATES; BIOLOGICAL RESPONSE MODIFIERS; CARCINOMA, RENAL CELL; CONTROLLED CLINICAL TRIALS; HUMANS; IMMUNOTHERAPY; INDOLES; INTERFERON-ALPHA; KIDNEY; KIDNEY NEOPLASMS; META-ANALYSIS; NEOPLASM METASTASIS; NEPHRECTOMY; PROGNOSIS; PROTEIN KINASE INHIBITORS; PYRIDINES; PYRROLES; TIME FACTORS;

EID: 34547776805     PISSN: 00017868     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2007-980093     Document Type: Article

References (18)

1. Coppin C, Porzsolt F, Awa A et al. Immunotherapy for advanced renal cell cancer. Cochrane Database Syst Rev 2005; (1): CD001425
2. Flanigan RC, Salmon SE, Blumenstein BA et al. Nephrectomy followed by interferon alfa-2b compared with interferon alfa-2b alone for metastatic renal-cell cancer. N Engl J Med Dec 6 2001 ; 345 (23): 1655-1659
3. Mickisch GH, Garin A, Poppel H van et al. Radical nephrectomy plus interferon-alfa-based immunotherapy compared with interferon alfa alone in metastatic renal-cell carcinoma: a randomised trial. Lancet Sep 22 2001 ; 358 (9286): 966-970
4. McDermott DF, Regan MM, Clark JI et al. Randomized phase III trial of high-dose interleukin-2 versus subcutaneous interleukin-2 and interferon in patients with metastatic renal cell carcinoma. J Clin Oncol Jan 12005:23(1): 133-141
5. Yang JC, Sherry RM, Steinberg SM et al. Randomized study of high-dose and low-dose interleukin-2 in patients with metastatic renal cancer. J Clin Oncol Aug 15 2003; 21 (16): 3127-3132
6. Gnarra JR, Tory K, Weng Y et al. Mutations of the VHL tumour suppressor gene in renal carcinoma. Nat Genet May 1994; 7 (1): 85 - 90
7. Motzer RJ, Hutson TE, Tomczak P et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med Jan 11 2007; 356 (2): 115-124
8. Motzer RJ, Bacik J, Murphy BA et al. Interferon-alfa as a comparative treatment for clinical trials of new therapies against advanced renal cell carcinoma. J Clin Oncol Jan 1 2002; 20 (1): 289-296
9. Hudes G, Carducci M, Tomczak P, Dutcher J, Figlin R, Kapoor A, Staroslawska E, O'Toole T, Park Y, Moore L. LBA4: A phase 3, randomized, 3-arm study of temsirolimus (TEMSR) or interferon-alpha (IFN) or the combination of TEMSR + IFN in the treatment of first-line, poor-risk patients with advanced renal cell carcinoma (adv RCC). Am Soc Clin Oncol Proc 2006; 24 (18 s Part II): 930s
10. Escudier B, Eisen T, Stadler WM et al. Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med Jan 11 2007; 356 (2): 125-134
11. Motzer RJ, Michaelson MD, Redman BG et al. Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma. J Clin Oncol Jan 1 2006; 24 (1): 16-24
12. Motzer RJ, Rini Bl, Bukowski RM et al. Sunitinib in patients with metastatic renal cell carcinoma. Jama Jun 7 2006; 295 (21): 2516 - 2524
13. Ratain MJ, Eisen T, Stadler WM et al. Phase II placebo-controlled randomized discontinuation trial of sorafenib in patients with metastatic renal cell carcinoma. J Clin Oncol Jun 1 2006; 24 (16): 2505-2512
14. Yang JC, Haworth L, Sherry RM et al. A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. N Engl J Med Jul 31 2003; 349 (5): 427-434
15. Negrier S, Escudier B, Lasset C et al. Recombinant human interleukin-2, recombinant human interferon alfa-2a, or both in metastatic renal-cell carcinoma. Groupe Francais d'Immunotherapie. N Engl J Med Apr 30 1998; 338 (18): 1272-1278
16. Atzpodien J, Kirchner H, Jonas U et al. Interleukin-2- and interferon alfa-2a-based immunochemotherapy in advanced renal cell carcinoma: a Prospectively Randomized Trial of the German Cooperative Renal Carcinoma Chemoimmunotherapy Group (DGCIN). J Clin Oncol Apr 1 2004; 22 (7): 1188-1194
17. Pyrhonen S, Salminen E, Ruutu M et al. Prospective randomized trial of interferon alfa-2a plus vinblastine versus vinblastine alone in patients with advanced renal cell cancer. J Clin Oncol Sep 1999; 17 (9): 2859-2867
18. Atzpodien J, Schmitt E, Gertenbach U et al. Adjuvant treatment with interleukin-2- and interferon-alpha2a-based chemoimmunotherapy in renal cell carcinoma post tumour nephrectomy: results of a prospectively randomised trial of the German Cooperative Renal Carcinoma Chemoimmunotherapy Group (DGCIN). Br J Cancer Mar 14 2005; 92 (5): 843-846